CN1997748A - 来自乳杆菌gg的益生化合物及其用途 - Google Patents

来自乳杆菌gg的益生化合物及其用途 Download PDF

Info

Publication number
CN1997748A
CN1997748A CNA2005800195831A CN200580019583A CN1997748A CN 1997748 A CN1997748 A CN 1997748A CN A2005800195831 A CNA2005800195831 A CN A2005800195831A CN 200580019583 A CN200580019583 A CN 200580019583A CN 1997748 A CN1997748 A CN 1997748A
Authority
CN
China
Prior art keywords
cell
compound
lactobacillus
protein
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800195831A
Other languages
English (en)
Chinese (zh)
Inventor
E·B·常
E·O·彭托夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of CN1997748A publication Critical patent/CN1997748A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2005800195831A 2004-04-20 2005-04-20 来自乳杆菌gg的益生化合物及其用途 Pending CN1997748A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56404904P 2004-04-20 2004-04-20
US60/564,049 2004-04-20

Publications (1)

Publication Number Publication Date
CN1997748A true CN1997748A (zh) 2007-07-11

Family

ID=35428847

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800195831A Pending CN1997748A (zh) 2004-04-20 2005-04-20 来自乳杆菌gg的益生化合物及其用途

Country Status (6)

Country Link
US (1) US20070123460A1 (enExample)
EP (1) EP1745142A4 (enExample)
JP (1) JP2008501316A (enExample)
CN (1) CN1997748A (enExample)
CA (1) CA2563702A1 (enExample)
WO (1) WO2005112976A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102575224A (zh) * 2009-09-11 2012-07-11 美赞臣营养品公司 用于预防和治疗过敏的益生菌衍生的无活力材料
CN113925884A (zh) * 2020-06-29 2022-01-14 创百股份有限公司 后生元提取物用于促进皮肤再生与抗老化的用途

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
BRPI0510004A (pt) * 2004-04-20 2007-09-18 Univ Chicago artigo de manufatura, métodos para administrar uma composição terapêutica a um epitélio de um indivìduo, para tratar uma condição mediada por micróbio de um epitélio de um indivìduo, para melhorar um sintoma de uma condição e para prevenir uma condição, e, uso de composto tipo peg pma
BRPI0611492B1 (pt) 2005-05-31 2021-10-13 Mars, Incorporated Bifidobactéria probiótica felina
JP4938005B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティックであるラクトバシラス
CA2673465A1 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal
CN101273737B (zh) * 2007-03-28 2011-08-24 哈尔滨正方科技有限公司 一种在常温下保持高活菌数的发酵乳饮料的制备方法
US9771199B2 (en) * 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
US8748381B2 (en) 2009-04-28 2014-06-10 Vanderbilt University Compositions and methods for the treatment of disorders involving epithelial cell apoptosis
US9848760B2 (en) * 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
US20120087902A1 (en) * 2009-07-20 2012-04-12 Bracco S.P.A. Therapeutic Use Of Probiotics
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US9730969B2 (en) 2015-11-06 2017-08-15 Mead Johnson Nutrition Company Nutritional compositions for promoting gut barrier function and ameliorating visceral pain
US20180161381A1 (en) * 2016-12-12 2018-06-14 Mead Johnson Nutrition Company Nutritional compositions and methods for reducing the occurrence or severity of viral infections, bacterial infections and viral and bacterial co-infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413785A (en) * 1993-01-27 1995-05-09 New England Deaconess Hospital Corp. Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
AU2001260791B2 (en) * 2000-05-25 2006-11-09 Nederlandse Organisatie Voor Toegepastnatuurwetenschappelijk Onderzoek Tno Fructosyltransferases (inulosucrase and levansucrase) from lactobacillus reuteri
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102575224A (zh) * 2009-09-11 2012-07-11 美赞臣营养品公司 用于预防和治疗过敏的益生菌衍生的无活力材料
CN113925884A (zh) * 2020-06-29 2022-01-14 创百股份有限公司 后生元提取物用于促进皮肤再生与抗老化的用途
CN113925884B (zh) * 2020-06-29 2024-05-14 创百股份有限公司 后生元提取物用于促进皮肤再生与抗老化的用途

Also Published As

Publication number Publication date
WO2005112976A2 (en) 2005-12-01
US20070123460A1 (en) 2007-05-31
EP1745142A4 (en) 2008-07-16
CA2563702A1 (en) 2005-12-01
EP1745142A2 (en) 2007-01-24
WO2005112976A3 (en) 2006-09-14
JP2008501316A (ja) 2008-01-24

Similar Documents

Publication Publication Date Title
Diling et al. Extracts from Hericium erinaceus relieve inflammatory bowel disease by regulating immunity and gut microbiota
US12127576B2 (en) Specific bacteria for their use as a medicament, in particular for controlling excess weight, obesity, cardiometabolic diseases and inflammatory bowel diseases
CN1997748A (zh) 来自乳杆菌gg的益生化合物及其用途
Salles Basic mechanisms of the aging gastrointestinal tract
Gu et al. Fusobacterium nucleatum causes microbial dysbiosis and exacerbates visceral hypersensitivity in a colonization-independent manner
BR112020023786A2 (pt) cepa kbl697 de lactobacillus gasseri e uso da mesma
RU2628536C2 (ru) Получение и применение бактериального гистамина
TWI602921B (zh) 用於治療及／或預防腹瀉的益生菌菌株
CN110833565B (zh) 植物乳杆菌gkm3的活性物质、含其的组合物及其促进长寿的用途
US11058733B2 (en) Active substances of Bifidobacterium lactis GKK2, composition comprising the same and method of promoting longevity using the same
AU2018397320B2 (en) Serpin production
Wang et al. A quinoa peptide protects impaired mucus barriers in colitis mice by inhibiting NF-κB-TRPV1 signaling and regulating the gut microbiota
KR20180110848A (ko) 신규한 락토바실러스 루테리 균주 및 그 프로바이오틱 용도
Ermolenko et al. Effects of indigenous enterococci on the intestinal microbiota and the behavior of rats on correction of experimental dysbiosis
WO2019129807A1 (en) Serpin production
Wang et al. Ageratina adenophora causes intestinal integrity damage in goats via the activation of the MLCK/ROCK signaling pathway
EP4000421A1 (en) Composition for ameliorating inflammatory bowel disease containing tisochrysis lutea
WO2018221627A1 (ja) スベリヒユ処理物、スベリヒユ処理物の製造方法、サプリメント、医薬品、腸管粘膜保護剤及び整腸剤
KR20060025607A (ko) 염증성 장 질환의 예방 및(또는) 치료제
Anbazhagan Gut-microbiota modulation: The impact of the gut-microbiota on osteoarthritis Vipin Arora", Gujit Singh"", Insflug o-Sullivan", Kaige Ma", Arivarasu Natarajan Anbazhagan “, E. Gina Votta-Velis", Benjamin Bruce", Ripper Richard “
CN118021917B (zh) 一种用于预防或治疗阿尔兹海默病的药物复方组合物及其应用
Nikolić Diabetes mellitus and obesity as a result of a disrupted homeostatic microbiome. New data on etiopathogenesis of diabetes mellitus
AU2006230772A1 (en) Probiotic compounds from lactobacillus GG and uses therefor
WO2024128252A1 (ja) ウコギ属植物地上部熱水抽出物の製造方法、ウログアニリン又はグアニリン発現促進用組成物、腸蠕動運動促進用組成物、腸炎症抑制用組成物及び腸バリア機能改善用組成物
Amdekar et al. Assessment of antiarthritic and immunomdulatory properties of Lactobacillus casei in collagen induced arthritis (CIA) experimental model

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070711